Studies focusing on c-MET inhibition has reported EGFR sensitivity towards erlotinib drug as well as erlotinib sensitization in a dominant-active c-Src subset of EGFR overexpressing HNSCC lines [94]. Here, SRC is linked to head and neck squamous cell carcinoma.